FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256206890> ?p ?o ?g. }

• W4256206890 abstract "The liver is affected by two of the most common groups of malignant tumours: primary liver tumours and liver metastases from colorectal carcinoma or other extrahepatic primary cancers. Liver metastases are significantly more common than primary liver cancer, and the reported long-term survival rate after radical surgical treatment is approximately 50%. However, R0 resection (resection for cure) is not feasible in the majority of patients; therefore, other treatments have to be considered. One of these is percutaneous ethanol injection (PEI), which causes dehydration and necrosis of tumour cells, accompanied by small-vessel thrombosis, leading to tumour ischaemia and destruction of the tumour.To assess the beneficial and harmful effects of percutaneous ethanol injection (PEI) compared with no intervention, other ablation methods, or systemic treatments in people with liver metastases.We searched the following databases up to 10 September 2019: the Cochrane Hepato-Biliary Group Controlled Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library; MEDLINE Ovid; Embase Ovid; Science Citation Index Expanded; Conference Proceedings Citation Index - Science; Latin American Caribbean Health Sciences Literature (LILACS); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). We also searched clinical trials registers such as ClinicalTrials.gov, the International Clinical Trials Registry Platform (ICTRP), and the US Food and Drug Administration (FDA) (17 September 2019).Randomised clinical trials assessing beneficial and harmful effects of percutaneous ethanol injection and its comparators (no intervention, other ablation methods, systemic treatments) for liver metastases.We followed standard methodological procedures as outlined by Cochrane. We extracted information on participant characteristics, interventions, study outcomes, study design, and trial methods. Two review authors performed data extraction and assessed risk of bias independently. We assessed the certainty of evidence by using GRADE. We resolved disagreements by discussion.We identified only one randomised clinical trial comparing percutaneous intratumour ethanol injection (PEI) in addition to transcatheter arterial chemoembolisation (TACE) versus TACE alone. The trial was conducted in China and included 48 trial participants with liver metastases: 25 received PEI plus TACE, and 23 received TACE alone. The trial included 37 male and 11 female participants. Mean participant age was 49.3 years. Sites of primary tumours included colon (27 cases), stomach (12 cases), pancreas (3 cases), lung (3 cases), breast (2 cases), and ovary (1 case). Seven participants had a single tumour, 15 had two tumours, and 26 had three or more tumours in the liver. The bulk diameter of the tumour on average was 3.9 cm, ranging from 1.2 cm to 7.6 cm. Participants were followed for 10 months to 43 months. The trial reported survival data after one, two, and three years. In the PEI + TACE group, 92%, 80%, and 64% of participants survived after one year, two years, and three years; in the TACE alone group, these percentages were 78.3%, 65.2%, and 47.8%, respectively. Upon conversion of these data to mortality rates, the calculated risk ratio (RR) for mortality at last follow-up when PEI plus TACE was compared with TACE alone was 0.69 (95% confidence interval (CI) 0.36 to 1.33; very low-certainty evidence) after three years of follow-up. Local recurrence was 16% in the PEI plus TACE group and 39.1% in the TACE group, resulting in an RR of 0.41 (95% CI 0.15 to 1.15; very low-certainty evidence). Forty-five out of a total of 68 tumours (66.2%) shrunk by at least 25% in the PEI plus TACE group versus 31 out of a total of 64 tumours (48.4%) in the TACE group. Trial authors reported some adverse events but provided very few details. We did not find data on time to mortality, failure to clear liver metastases, recurrence of liver metastases, health-related quality of life, or time to progression of liver metastases. The single included trial did not provide information on funding nor on conflict of interest.Evidence for the effectiveness of PEI plus TACE versus TACE in people with liver metastases is of very low certainty and is based on one small randomised clinical trial at high risk of bias. Currently, it cannot be determined whether adding PEI to TACE makes a difference in comparison to using TACE alone. Evidence for benefits or harms of PEI compared with no intervention, other ablation methods, or systemic treatments is lacking." @default.
• W4256206890 created "2022-05-12" @default.
• W4256206890 creator A5011926383 @default.
• W4256206890 creator A5013315390 @default.
• W4256206890 creator A5023272149 @default.
• W4256206890 creator A5023787213 @default.
• W4256206890 creator A5029658912 @default.
• W4256206890 creator A5069841995 @default.
• W4256206890 creator A5075448540 @default.
• W4256206890 creator A5091800586 @default.
• W4256206890 date "2020-02-04" @default.
• W4256206890 modified "2023-10-16" @default.
• W4256206890 title "Percutaneous ethanol injection for liver metastases" @default.
• W4256206890 cites W1859414766 @default.
• W4256206890 cites W1927653039 @default.
• W4256206890 cites W1964489041 @default.
• W4256206890 cites W1964502734 @default.
• W4256206890 cites W1971441597 @default.
• W4256206890 cites W1975154077 @default.
• W4256206890 cites W1977403970 @default.
• W4256206890 cites W1979538859 @default.
• W4256206890 cites W1982527376 @default.
• W4256206890 cites W2004709760 @default.
• W4256206890 cites W2006175454 @default.
• W4256206890 cites W2011932878 @default.
• W4256206890 cites W2014996730 @default.
• W4256206890 cites W2020830322 @default.
• W4256206890 cites W2022142302 @default.
• W4256206890 cites W2040222657 @default.
• W4256206890 cites W2040935952 @default.
• W4256206890 cites W2042916800 @default.
• W4256206890 cites W2045368439 @default.
• W4256206890 cites W2049852456 @default.
• W4256206890 cites W2053975874 @default.
• W4256206890 cites W2055469806 @default.
• W4256206890 cites W2065384164 @default.
• W4256206890 cites W2075642745 @default.
• W4256206890 cites W2079878657 @default.
• W4256206890 cites W2088095316 @default.
• W4256206890 cites W2091577000 @default.
• W4256206890 cites W2096266245 @default.
• W4256206890 cites W2103352649 @default.
• W4256206890 cites W2104507889 @default.
• W4256206890 cites W2107328434 @default.
• W4256206890 cites W2110970000 @default.
• W4256206890 cites W2117294447 @default.
• W4256206890 cites W2123874025 @default.
• W4256206890 cites W2125892433 @default.
• W4256206890 cites W2127327506 @default.
• W4256206890 cites W2133774931 @default.
• W4256206890 cites W2134338262 @default.
• W4256206890 cites W2138188443 @default.
• W4256206890 cites W2144326782 @default.
• W4256206890 cites W2147802232 @default.
• W4256206890 cites W2150000105 @default.
• W4256206890 cites W2157604272 @default.
• W4256206890 cites W2157823046 @default.
• W4256206890 cites W2158734599 @default.
• W4256206890 cites W2160795579 @default.
• W4256206890 cites W2164905752 @default.
• W4256206890 cites W2166023752 @default.
• W4256206890 cites W2168083201 @default.
• W4256206890 cites W2171811563 @default.
• W4256206890 cites W2235523093 @default.
• W4256206890 cites W2248147052 @default.
• W4256206890 cites W2270274212 @default.
• W4256206890 cites W2274509377 @default.
• W4256206890 cites W2277004004 @default.
• W4256206890 cites W2280957887 @default.
• W4256206890 cites W2437305821 @default.
• W4256206890 cites W2529326258 @default.
• W4256206890 cites W2560322684 @default.
• W4256206890 cites W2587635030 @default.
• W4256206890 cites W2593363470 @default.
• W4256206890 cites W2607053343 @default.
• W4256206890 cites W2735126203 @default.
• W4256206890 cites W2765432991 @default.
• W4256206890 cites W2767350488 @default.
• W4256206890 cites W2787553551 @default.
• W4256206890 cites W2793084102 @default.
• W4256206890 cites W2802039131 @default.
• W4256206890 cites W2930464194 @default.
• W4256206890 cites W4210955410 @default.
• W4256206890 cites W4214559180 @default.
• W4256206890 cites W4236946551 @default.
• W4256206890 cites W4237839136 @default.
• W4256206890 cites W4238114855 @default.
• W4256206890 cites W4246026256 @default.
• W4256206890 cites W4256206890 @default.
• W4256206890 doi "https://doi.org/10.1002/14651858.cd008717.pub3" @default.
• W4256206890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32017845" @default.
• W4256206890 hasPublicationYear "2020" @default.
• W4256206890 type Work @default.
• W4256206890 citedByCount "7" @default.
• W4256206890 countsByYear W42562068902020 @default.
• W4256206890 countsByYear W42562068902021 @default.
• W4256206890 countsByYear W42562068902022 @default.
• W4256206890 countsByYear W42562068902023 @default.
• W4256206890 crossrefType "journal-article" @default.
• W4256206890 hasAuthorship W4256206890A5011926383 @default.

• next